抑制整合素VLA-3与四跨膜蛋白CD151可防止中性粒细胞介导的内皮损伤
该研究从脓毒症患者或健康供者取血纯化中性粒细胞,用TNF-α活化人脐静脉内皮细胞,以电阻抗传感测定单层电阻。脓毒症患者中性粒细胞及体外活化的中性粒细胞较健康供者中性粒细胞更大幅度降低内皮单层电阻;用抗体阻断VLA-3和/或CD151可显著减少活化相关内皮损伤,且在纤连蛋白、I型胶原、IV型胶原和层粘连蛋白上结果相似。作者认为中性粒细胞表面VLA-3和CD151是内皮功能损伤的原因,体内靶向这些分子可能保护危重症时的器官功能。
要点
- 脓毒症患者中性粒细胞和体外活化的中性粒细胞较健康供者中性粒细胞更大幅度降低内皮单层电阻。
- 抗体阻断VLA-3和/或CD151可显著减少活化相关内皮损伤。
- 在纤连蛋白、I型胶原、IV型胶原和层粘连蛋白上结果相似,提示损伤不依赖基底膜成分。
- 作者认为靶向VLA-3和CD151在体内可能保护危重症时的器官功能。
适用人群与场景
- 脓毒症患者与健康供者外周血纯化的中性粒细胞;体外活化的人脐静脉内皮细胞单层。
研究设计与关键结果
- 研究类型为体外实验:取脓毒症患者或健康供者血液纯化中性粒细胞,部分经促炎分子处理,人脐静脉内皮细胞经TNF-α活化,电阻抗传感测定单层电阻。
- 脓毒症患者中性粒细胞及体外活化的中性粒细胞较健康供者中性粒细胞更大幅度降低内皮单层电阻。
- 抗体阻断VLA-3和/或CD151显著减少活化相关内皮损伤。
- 在纤连蛋白、I型胶原、IV型胶原和层粘连蛋白上结果相似,提示中性粒细胞表面VLA-3和CD151导致的内皮损伤不依赖基底膜成分。
证据类型、等级与局限
- 证据类型:体外实验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,体内靶向VLA-3和CD151可能保护危重症时的器官功能。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Background: The recruitment of neutrophils to sites of localized injury or infection is initiated by changes on the surface of endothelial cells located in proximity to tissue damage. Inflammatory mediators, such as TNF-α, increase surface expression of adhesive ligands and receptors on the endothelial surface to which neutrophils tether and adhere. Neutrophils then transit through the activated endothelium to reach sites of tissue injury with little lasting vascular injury. However, in cases of sepsis, the interaction of endothelial cells with highly activated neutrophils can cause damage vascular damage. The identification of molecules that are essential for neutrophil diapedesis may reveal targets of therapeutic opportunity for preservation of endothelial function in the presence of critical illness. We tested the hypothesis that inhibition of neutrophil β1 integrin very late antigen-3 (VLA-3; α3β1) and/or inhibition of the tetraspanin (TM4) family member CD151 would protect against neutrophil-mediated loss of endothelial function. Methods: Blood was obtained from septic patients or healthy donors. Neutrophils were purified, and aliquots were treated with/without proinflammatory molecules. Confluent human umbilical vascular endothelial cells were activated with TNF-α. Electric cell impedance sensing was used to determine monolayer resistance over time after the addition of neutrophils that were treated with blocking antibodies against VLA-3 and/or CD151 or isotype controls. Groups (depending on relevancy) were analyzed by Mann-Whitney U test, Wilcoxon test, or repeated-measures one-way ANOVA. Results: Neutrophils from septic patients and neutrophils activated ex vivo reduced endothelial monolayer resistance to a greater extent than neutrophils from healthy donors. Antibody blockade of VLA-3 and/or CD151 significantly reduced activation-associated endothelial damage. Similar findings were demonstrated on fibronectin, collagen I, collagen IV, and laminin, suggesting that neutrophil surface VLA-3 and CD151 are responsible for endothelial damage regardless of substrata and are likely to be operative in all bodily tissues. Conclusion: This report identifies VLA-3 and CD151 on the activated human neutrophil, which are responsible for damage to endothelial function. Targeting these molecules in vivo may demonstrate preservation of organ function during critical illness.
参考来源
- Ciambella C, Witt H, Dickinson CM, et al. INHIBITION OF INTEGRIN VLA-3 AND TETRASPANIN CD151 PROTECTS AGAINST NEUTROPHIL-MEDIATED ENDOTHELIAL DAMAGE. Shock. 2024. PMID: 38813923. doi:10.1097/SHK.0000000000002397
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。